Cordex Biologics
San Diego, United States· Est.
Cordex uses UM171‑expanded stem cells to deliver curative, one‑time cell therapies for transplant patients.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Cordex uses UM171‑expanded stem cells to deliver curative, one‑time cell therapies for transplant patients.
HematologyOncology
Technology Platform
Proprietary UM171 small‑molecule that expands human hematopoietic stem and progenitor cells ex vivo, enabling a one‑time curative cell therapy product.
Opportunities
Successful Phase 3 data and regulatory approval could position Cordex as a leading provider of curative stem cell therapies, opening reimbursement opportunities across hematology and oncology.
Risk Factors
Key risks include clinical trial outcomes, manufacturing scale‑up challenges, and competition from alternative HSC expansion technologies.
Competitive Landscape
Cordex differentiates through UM171‑mediated expansion, offering higher engraftment efficiency than competing ex‑vivo platforms, but must compete with established cell therapy developers and emerging gene‑editing approaches.